Breast Cancer Clinical Trial

A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors

Summary

The main purpose of this study is to evaluate the safety of the study drug known as LY3039478 in combination with other anticancer agents in participants with advanced or metastatic solid tumors.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

For all parts: The participant must be, in the judgment of the investigator, an appropriate candidate for experimental therapy after available standard therapies have failed to provide clinical benefit for their advanced or metastatic cancer.

For dose escalation for all combinations: The participant must have histological or cytological evidence of cancer, either a solid tumor or a lymphoma, which is advanced or metastatic.
For Part A dose confirmation: All participants must have histological evidence of advanced or metastatic soft tissue sarcoma or breast cancer. Breast cancer participants must have prescreened mutations, amplification, or gene/protein expression alterations related to Notch pathway.
For Part B dose confirmation: All participants must have histological evidence of advanced or metastatic colon cancer or soft tissue sarcoma. Colon cancer participants must have prescreened mutations, amplification, or gene/protein expression alterations related to Notch pathway.
For Part C dose confirmation: All participants must have histological evidence of advanced or metastatic breast cancer and prescreened mutations, amplification, or gene/protein expression alterations related to Notch pathway.
For Part D dose confirmation: All participants must have histological evidence of cholangiocarcinoma and prescreened mutations, amplification, or gene/protein expression alterations related to Notch pathway. Participants must not have received >1 line of prior systemic therapy for metastatic or resectable disease (that is, participants may have received adjuvant gemcitabine and then later gemcitabine/cisplatin for recurrent metastatic disease).
For Part E dose confirmation: All participants must have histological evidence of locally advanced or metastatic triple negative breast cancer (TNBC) and prescreened mutations, amplification, or gene/protein expression alterations related to Notch pathway. Participants must not have received >2 lines of systemic treatment for advanced or metastatic TNBC.
Have adequate organ function.
Have a performance status of ≤1 on the Eastern Cooperative Oncology Group (ECOG) scale.
Have discontinued all previous therapies for cancer.

Exclusion Criteria:

Have current acute leukemia.
Have current or recent (within 3 months of study drug administration) gastrointestinal disease with chronic or intermittent diarrhea, or disorders that increase the risk of diarrhea, such as inflammatory bowel disease.

Study is for people with:

Breast Cancer

Phase:

Phase 1

Estimated Enrollment:

94

Study ID:

NCT02784795

Recruitment Status:

Completed

Sponsor:

Eli Lilly and Company

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 11 Locations for this study

See Locations Near You

Sylvester Comprehensive Cancer Center
Miami Florida, 33136, United States
Karmanos Cancer Institute
Detroit Michigan, 48201, United States
Memorial Sloan Kettering Cancer Center
New York New York, 10065, United States
University of Texas MD Anderson Cancer Center
Houston Texas, 77030, United States
Rigshospitalet
Copenhagen København Ø, 2100, Denmark
Institut Bergonie
Bordeaux , 33076, France
Centre Leon Berard
Lyon Cedex 08 , 69373, France
Gustave Roussy
Villejuif Cedex , 94805, France
Hospital Universitari Vall d'Hebron
Barcelona , 08035, Spain
Fundacion Jimenez Diaz
Madrid , 28040, Spain
Hospital Madrid Norte Sanchinarro
Madrid , 28050, Spain

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Phase:

Phase 1

Estimated Enrollment:

94

Study ID:

NCT02784795

Recruitment Status:

Completed

Sponsor:


Eli Lilly and Company

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider